Dr. Janessa Laskin, MD
Claim this profileBC Cancer
Studies Lung Cancer
Studies Breast Cancer
5 reported clinical trials
9 drugs studied
Area of expertise
1Lung Cancer
Stage III
RET positive
Stage IV
2Breast Cancer
RET positive
Stage III
NRG1 positive
Affiliated Hospitals
Clinical Trials Janessa Laskin, MD is currently running
LY3537982 + Immunotherapy/Chemotherapy
for Non-Small Cell Lung Cancer
This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.
Recruiting1 award Phase 314 criteria
Atezolizumab
for Cancer
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and their cancer. This is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is completed, and will involve approximately 200 participants. Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). In the first stage for each cohort, 8 participants will be enrolled and if no participants respond to treatment, enrollment to that cohort will be closed. If 1 or more participants respond to treatment, up to 16 additional participants will be enrolled to that cohort. Participants continue on treatment until they no longer may benefit from the treatment or they decide to stop treatment.
Recruiting1 award Phase 210 criteria
More about Janessa Laskin, MD
Clinical Trial Related5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Janessa Laskin, MD has experience with
- Atezolizumab
- Genome Sequencing
- Seribantumab
- LOXO-292
- Carboplatin
- Cisplatin
Breakdown of trials Janessa Laskin, MD has run
Lung Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Janessa Laskin, MD specialize in?
Janessa Laskin, MD focuses on Lung Cancer and Breast Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are RET positive.
Is Janessa Laskin, MD currently recruiting for clinical trials?
Yes, Janessa Laskin, MD is currently recruiting for 3 clinical trials in Vancouver British Columbia. If you're interested in participating, you should apply.
Are there any treatments that Janessa Laskin, MD has studied deeply?
Yes, Janessa Laskin, MD has studied treatments such as Atezolizumab, Genome sequencing, Seribantumab.
What is the best way to schedule an appointment with Janessa Laskin, MD?
Apply for one of the trials that Janessa Laskin, MD is conducting.
What is the office address of Janessa Laskin, MD?
The office of Janessa Laskin, MD is located at: BC Cancer, Vancouver, British Columbia V5Z 4E6 Canada. This is the address for their practice at the BC Cancer.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.